

Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients

*This measure is to be reported for all patients aged 18 through 75 years with diabetes mellitus — a minimum of **once** per reporting period.*

Measure description

Percentage of patients aged 18 through 75 years with diabetes mellitus who received urine protein screening or medical attention for nephropathy during at least one office visit within 12 months

What will you need to report for each patient with diabetes mellitus for this measure?

If you select this measure for reporting, you will report:

- Whether or not you performed a nephropathy screening or documented the patient is already receiving treatment for nephropathy

Patients will fall into one of the categories described below:

- Nephropathy screening performed
 - Positive microalbuminuria test documented and reviewed
 - Negative microalbuminuria test documented and reviewed
 - Positive macroalbuminuria test documented and reviewed
- Patient receiving treatment for nephropathy
 - Documentation of treatment for nephropathy (eg, patient receiving dialysis, patient being treated for ESRD, CRF, ARF, or renal insufficiency, any visit to a nephrologist)
 - Angiotensin converting enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) therapy prescribed

What if this process or outcome of care is not appropriate for your patient?

Some measures provide an opportunity for the physician or eligible health professional to document when a process or outcome of care is not appropriate for a given patient (also called performance exclusions). Because this measure is applicable to most if not all patients, there are no allowable performance exclusions.